黄连多糖抗蛋白质非酶糖基化活性初步研究  

Antiglycation of polysaccharides from Coptis chinensis

作　　者：李敏[1] 金晶[1] 叶新[1] 刘秋爽[1] 唐晓宇[1] 钱铭[1] 曹妍[1] 张良栓[1] 

机构地区：[1]哈尔滨医科大学药学院,哈尔滨150081

出　　处：《黑龙江大学自然科学学报》2014年第2期223-227,共5页Journal of Natural Science of Heilongjiang University

基　　金：黑龙江省卫生厅科研课题资助项目(2013144)

摘　　要：初步研究了黄连多糖对体外蛋白质非酶糖基化过程的抑制作用。应用化学方法建立蛋白质非酶糖基化反应模型,以氨基胍为阳性对照,考察黄连多糖对蛋白质非酶糖基化过程中Amadori产物、二羰基化合物及蛋白质非酶糖基化终产物(AGEs)的生成这三个阶段的影响。实验结果表明,黄连多糖可以从糖基化反应的三个阶段来抑制AGEs的生成,在不同浓度下均具有很强的抑制作用,且对Amadori产物生成的抑制作用强于阳性对照氨基胍(p<0.05,n=3)。这提示黄连多糖可能为中药黄连中抑制糖尿病的活性物质。根据糖尿病并发症的产生机制,黄连多糖有可能成为价廉、无毒的糖尿病并发症抑制或治疗药物。Antiglycation of polysaccharides from Coptis ehinensis （CP） was studied. The model of glyeation was established based on a chemical method. The CP effect on the formation of amadori prod- uets, diearbonyl compounds and AGEs were investigated with amino guanidine as a positive reference. The results showed that the CP obviously suppressed the three stages of AGEs generated from the glyeosy- lation reaction, especially on the formation of amadori products, which was stronger than amino guanidine （p 〈 0. 05, n = 3 ）. This experiment implied that CP was effective for preventing and treating diabetic complications. Therefore, CP has potential to become an inexpensive, relatively less toxic therapy to pre- vent and treat diabetic complications.

关 键 词：黄连 多糖 蛋白质非酶糖基化 糖尿病 

分 类 号：R587.1[医药卫生—内分泌]